Exact Sciences

EXAS65

$55.14arrow_drop_up4.30%$2.28

EXAS65

$55.14

arrow_drop_up4.30%$2.28

Performance History

Key Stats
Open	$53.10
Prev. Close	$52.91
EPS	-1.16
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	52.82	61.07
52 Week Range	40.62	79.62

Ratios







EPS	-1.16

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Exact Sciences (EXAS)

Exact Sciences Corp (EXAS) is a molecular diagnostics company that is focused on the early detection and prevention of some of the deadliest forms of cancer. The company's flagship product is Cologuard, a noninvasive DNA screening test for colorectal cancer. Cologuard is able to detect DNA alterations and other biomarkers associated with colorectal cancer, which allows for early detection and potentially life-saving intervention. In addition to Cologuard, Exact Sciences is also developing a pipeline of other diagnostic tests for various types of cancer, including lung cancer and pancreatic cancer.

The stock price history of Exact Sciences Corp has been quite volatile in recent years. The company's stock price has experienced significant fluctuations, with periods of rapid growth followed by periods of decline. However, in recent years, the stock has been on an upward trend, reaching new all-time highs. This can be attributed to several factors, including the success of Cologuard and the growing demand for noninvasive cancer screening tests. Investors are optimistic about the potential of Exact Sciences' pipeline of diagnostic tests, which could further drive the stock price higher in the future.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Mr. Kevin T. Conroy
Headquarters: Madison
Employees: 6300
Exchange: NASDAQ

Keep an eye on Exact Sciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Exact Sciences's (EXAS) price per share?

The current price per share for Exact Sciences (EXAS) is $55.14. The stock has seen a price change of $2.28 recently, indicating a 4.31% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Exact Sciences (EXAS)?

For Exact Sciences (EXAS), the 52-week high is $79.62, which is 44.4% from the current price. The 52-week low is $40.62, the current price is 35.75% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Exact Sciences (EXAS) a growth stock?

Exact Sciences (EXAS) has shown an average price growth of -3.36% over the past three years. It has received a score of 37 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Exact Sciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Exact Sciences (EXAS) stock price performance year to date (YTD)?

As of the latest data, Exact Sciences (EXAS) has a year-to-date price change of -25.25%. Over the past month, the stock has experienced a price change of -20.21%. Over the last three months, the change has been -7.85%. Over the past six months, the figure is 17.27%. Looking at a longer horizon, the five-year price change stands at -32.53%.

help

Is Exact Sciences (EXAS) a profitable company?

Exact Sciences (EXAS) has a net income of -$204.15M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.83% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.61% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.5B, with a revenue growth rate of 19.93%, providing insight into the company's sales performance and growth. The gross profit is $1.85B. Operating income is noted at -$215.01M. Furthermore, the EBITDA is -$11.34M.

help

What is the market capitalization of Exact Sciences (EXAS)?

Exact Sciences (EXAS) has a market capitalization of $10.21B. The average daily trading volume is 54.89, indicating the stock's liquidity and investor engagement.